UPDATE: Citi Upgrades Eli Lilly (LLY) to Buy

Citi upgraded Eli Lilly (NYSE: LLY) from Neutral to Buy with a price target of $100. Analysts raised evacetrapib risk peak sales estimates from $1 billion to $3.8 billion. The change follows Merck (NYSE: MRK) IMPROVE-IT data that showed its Vytorin validates cardio benefit of lowering LDL cholesterol with a non-statin agent.

For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.

Shares of Eli Lilly closed at $71.18 yesterday.

You May Also Be Interested In

• Piper Sandler Upgrades Tempus AI Inc (TEM) to Overweight, 'On A Train Back To Upside, We're Not Jumping the Gun'
• UBS Downgrades AREIT Inc (AREIT:PM) to Neutral
• Piper Sandler Double Downgrades Myriad Genetics (MYGN) to Underweight, 'Major Strategic Action Likely Needed'